J Liver Cancer.  2024 Sep;24(2):274-285. 10.17998/jlc.2024.08.13.

Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study

• Han JW
• Sohn W
• Choi GH
• Jang JW
• Seo GH
• Kim BH
• Choi JY

• KMID: 2559474
• DOI: http://doi.org/10.17998/jlc.2024.08.13

Abstract

Backgrounds/Aims
The treatment landscape for hepatocellular carcinoma (HCC) has significantly evolved over the past decade. We aimed to analyze trends in treatment patterns for HCC using a nationwide claims database from the Korean Health Insurance Review and Assessment Service.
Methods
This retrospective population-based cohort study analyzed 171,002 newly diagnosed HCC patients between 2008 and 2022. Etiologies and treatment modalities were categorized based on the ICD-10 codes and insurance data.
Results
The annual incidence decreased from 11,814 in 2008 to 10,443 in 2022. However, patients aged ≥70 increased noticeably, with those aged ≥80 rising from 3.8% in 2008 to 13.1% in 2022. From 2008 to 2022, the predominant cause of hepatitis B virus decreased from 68.9% to 59.7%, whereas nonalcoholic fatty liver disease increased from 8.9% to 15.8%. The initial treatment trends shifted: surgical resection and systemic therapy increased from 12.2% to 21.3% and from 0.2% to 9.6%, whereas transarterial therapy decreased from 49.9% to 36.6%. Best supportive care decreased from 31.7% to 21.3%. In the subgroup analysis, laparoscopic resection rate increased from 10.6% to 60.6% among the surgical resections. Sorafenib initially accounted for 100%, lenvatinib peaked at 36.5% in 2021, and atezolizumab-bevacizumab became the most widely used (63.1%) by 2022 among the systemic therapies.
Conclusions
This study demonstrates the temporal changes in the treatment patterns of Korean HCC patients. Surgical resection, particularly laparoscopic liver resection, and systemic therapy has increased significantly. These changes may have been influenced by reimbursement policies and advances in clinical research.

Keyword

Hepatocellular carcinoma; Clinical practice patterns; Korea

Figure

• 

  Figure 1. Study flow chart regarding initial treatments for HCC. HCC, hepatocellular carcinoma.

• 

  Figure 2. Comparison of the trends in incidence of HCC by age group and etiology between 2008 and 2022. (A) The percentage of HCC incidence by age group. (B) The percentage of HCC incidence by etiology. HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; NAFLD, nonalcoholic fatty liver disease.

• 

  Figure 3. Initial treatments for HCC from 2008 to 2022. (A) Total cases and percentages of each treatment. (B) Comparison of initial treatment percentages between 2008 and 2022. HCC, hepatocellular carcinoma.

• 

  Figure 4. Subgroup analysis by each initial treatment modality. (A) Percentages of open and laparoscopic resections among surgical resections. (B) Percentages of RFA, MWA, and cryoablation among local ablation treatments. (C) Percentages of cTACE, DEB-TACE, TARE, and other treatments among transarterial therapies. (D) Number and percentage of patients who received sorafenib, lenvatinib, and atezolizumab-bevacizumab. RFA, radiofrequency ablation; MWA, microwave ablation; cTACE, conventional transarterial chemoembolization; DEB-TACE, drug-eluting bead transarterial chemoembolization; TARE, transarterial radioembolization.

• 

  Figure 5. Status of first-line systemic therapy in patients with HCC regardless of prior loco-regional therapy. (A) Annual number of patients who received sorafenib, lenvatinib, and atezolizumab-bevacizumab from 2008 to 2022. (B) Number of patients and the percentages of each regimen by quarter, from the first quarter of 2019 to the first quarter of 2023. (C) Comparison of the percentages of each regimen between the first quarter of 2019, the second quarter of 2020, and the first quarter of 2023. HCC, hepatocellular carcinoma.

• 

Reference

References

1. Kang MJ, Jung KW, Bang SH, Choi SH, Park EH, Yun EH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2020. Cancer Res Treat. 2023; 55:385–399.

2. Chon YE, Lee HA, Yoon JS, Park JY, Kim BH, Lee IJ, et al. Hepatocellular carcinoma in Korea between 2012 and 2014: an analysis of data from the Korean Nationwide Cancer Registry. J Liver Cancer. 2020; 20:135–147.

3. Singal AG, Kudo M, Bruix J. Breakthroughs in hepatocellular carcinoma therapies. Clin Gastroenterol Hepatol. 2023; 21:2135–2149.

4. Lee JS, Kim JM, Lee S, Choi JY, Cho W, Choi GS, et al. The prognosis in cases of hepatocellular carcinoma after hepatectomy: young patients versus older patients. Korean J Hepatobiliary Pancreat Surg. 2015; 19:154–160.

5. Park GC, Hwang S, Park YH, Choi JU; Korean Liver Cancer Study Group. Validation of prognostic impact of ADV score for resection of hepatocellular carcinoma: analysis using Korea Liver Cancer Registry database. Ann Surg Treat Res. 2020; 98:235–246.

6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359:378–390.

7. Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391:1163–1173.

8. Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022; 76:862–873.

9. Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022; 1:EVIDoa2100070.

10. Korean Liver Cancer Association (KLCA); National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022; 28:583–705.

11. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022; 76:681–693.

12. Chon YE, Jeong SW, Jun DW. Hepatocellular carcinoma statistics in South Korea. Clin Mol Hepatol. 2021; 27:512–514.

13. Kyoung DS, Kim HS. Understanding and utilizing claim data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) database for research. J Lipid Atheroscler. 2022; 11:103–110.

14. Kim JA, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci. 2017; 32:718–728.

15. Pinheiro PS, Jones PD, Medina H, Cranford HM, Koru-Sengul T, Bungum T, et al. Incidence of etiology-specific hepatocellular carcinoma: diverging trends and significant heterogeneity by race and ethnicity. Clin Gastroenterol Hepatol. 2024; 22:562–571.e8.

16. Park EH, Jung KW, Park NJ, Kang MJ, Yun EH, Kim HJ, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2021. Cancer Res Treat. 2024; 56:357–371.

17. Cho Y, Kim BH, Park JW. The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea. Clin Mol Hepatol. 2023; 29:99–101.

18. Kim YJ, Jang BK, Kim ES, Chung WJ, Park KS, Cho KB, et al. Hepatocellular carcinoma in the elderly: clinical characteristics, treatment, survival analysis in Korean patients older than 70 years. J Korean Med Sci. 2012; 27:1147–1154.

19. Torimura T, Iwamoto H. Optimizing the management of intermediatestage hepatocellular carcinoma: current trends and prospects. Clin Mol Hepatol. 2021; 27:236–245.

20. Hatanaka T, Kakizaki S, Hiraoka A, Kariyama K, Tsuji K, Ishikawa T, et al. The prognosis of elderly patients with hepatocellular carcinoma: a multicenter 19-year experience in Japan. Cancer Med. 2023; 12:345–357.

21. Kim BH, Lim YS, Kim EY, Kong HJ, Won YJ, Han S, et al. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population. J Gastroenterol Hepatol. 2018; 33:475–483.

22. Sohn W, Kang D, Kang M, Guallar E, Cho J, Paik YH. Impact of nationwide hepatocellular carcinoma surveillance on the prognosis in patients with chronic liver disease. Clin Mol Hepatol. 2022; 28:851–863.

23. Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, Okolo E, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res (Phila). 2012; 5:1124–1130.

24. Schneider CV, Schneider KM, Raptis A, Huang H, Trautwein C, Loomba R. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population. Aliment Pharmacol Ther. 2024; 59:1271–1281.

25. Bae H, Lee SA, Choi JW, Hwang SH, Park S, Park MS. Effectiveness of hepatocellular carcinoma surveillance and an optimal surveillance interval: nationwide cohort of Korea. Yonsei Med J. 2021; 62:758–766.

26. Chieh AKW, Chan A, Rotellar F, Kim KH. Laparoscopic major liver resections: current standards. Int J Surg. 2020; 82 Suppl:169–177.

27. Ciria R, Gomez-Luque I, Ocaña S, Cipriani F, Halls M, Briceño J, et al. A systematic review and meta-analysis comparing the short- and longterm outcomes for laparoscopic and open liver resections for hepatocellular carcinoma: updated results from the European guidelines meeting on laparoscopic liver surgery, Southampton, UK, 2017. Ann Surg Oncol. 2019; 26:252–263.

28. Witowski J, Rubinkiewicz M, Mizera M, Wysocki M, Gajewska N, Sitkowski M, et al. Meta-analysis of short- and long-term outcomes after pure laparoscopic versus open liver surgery in hepatocellular carcinoma patients. Surg Endosc. 2019; 33:1491–1507.